DCU Biomaterials Research Group, funded by Enterprise Ireland, is a commercially focused group who work closely with other groups within as well as outside DCU to develop innovative medical devices. The group works with clinicians and radiologists as well as external marketing and regulatory consultants to bring novel products to market. The group is currently focused on the development of novel injectable biomaterials for the treatment of cerebral aneurysms, embolic materials for the treatment of liver tumours and the development of angiogenic biomaterials for the treatment of peripheral artery disease. The group has a wide variety of expertise, including orthopaedic and vascular biomaterials, organic and inorganic chemistry and engineering. The group has a large quantity of state of the art materials manufacturing, processing and analytical equipment at its disposal and has access to a full cell culture suite.